ScholarMate
WeChat
Sina
Facebook
Share link
Summary
Objective This study aimed to compare [Ga-68]Ga-FAPI-04/[F-18]FAPI-42 PET/CT with [F-18]FDG PET/CT in the evaluation of initial gastric cancer. Methods We retrospectively compared [Ga-68]Ga-FAPI-04/[F-18]FAPI-42 PET/CT with [F-18]FDG PET/CT in patients with initial gastric cancer from September 2020 to March 2021. Lesion detectability and the uptake of lesions quantified by the maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR) were compared between the two modalities using the Wilcoxon signed-rank test, Mann-Whitney U test, and McNemar's chi-square test. Results A total of 61 patients (37 males, aged 23-81 years) were included, of which 22 underwent radical gastrectomy. For primary lesions, higher uptake of [Ga-68]Ga-FAPI-04/[F-18]FAPI-42 was observed compared to [F-18]FDG (median SUVmax, 14.60 vs 4.35, p < 0.001), resulting in higher positive detection using [Ga-68]Ga-FAPI-04/[F-18]FAPI-42 PET/CT than [F-18]FDG PET/CT (95.1% vs 73.8%, p < 0.001), particularly for tumors with signet-ring cell carcinoma (SRCC) (96.4% vs 57.1%, p < 0.001). [Ga-68]Ga-FAPI-04/[F-18]FAPI-42 PET/CT detected more positive lymph nodes than [F-18]FDG PET/CT (637 vs 407). However, both modalities underestimated N staging compared to pathological N staging. [Ga-68]Ga-FAPI-04/[F-18]FAPI-42 PET/CT showed a higher sensitivity (92.3% vs 53.8%, p = 0.002) and peritoneal cancer index score (18 vs 3, p < 0.001) in peritoneum metastasis and other suspect metastases compared to [F-18]FDG PET/CT. Conclusion Our findings indicate that [Ga-68]Ga-FAPI-04/[F-18]FAPI-42 PET/CT outperformed [F-18]FDG PET/CT in the evaluation of primary tumors with SRCC and peritoneum metastasis in initial gastric cancer. However, no clinically useful improvement was seen in N staging.
-
Institution南方医科大学
